There was a 21% reduction in MACE, an exploratory endpoint, in the obicetrapib group vs placebo after 1 year. Obicetrapib reduced LDL-C in patients with atherosclerotic cardiovascular disease and/or ...

The topline results from the Phase III trial found the treatment to be well tolerated with a reduction in low-density ...

Researchers reveal the structural details of apoB100's interaction with LDL receptors, offering insights into LDL ...

THERE ARE MANY misconceptions about important cardiovascular metrics. Often people think their risk of heart disease and ...

Our top content from the 100th annual American Heart Association (AHA) Scientific Sessions included exclusive expert insights ...

Menarini Group announces positive topline data from pivotal phase 3 BROADWAY & TANDEM trials of Obicetrapib and FDC Obicetrapib with Ezetimibe 10 mg: Florence, Italy Wednesday, De ...

lipoprotein(a), apolipoprotein B, and apolipoprotein A1, were also found to be consistent with previous clinical trials. Notably, there was a 21% reduction in major adverse cardiovascular events ...

Study deciphers the molecular handshake between LDL receptors and apoB100, shedding light on cholesterol metabolism and its role in cardiovascular disease. Study: Structure of apolipoprotein B100 ...

A recent study confirms that unprocessed beef can be part of a heart-healthy diet without raising cardiovascular disease risk ...

A new study published in the journal of International Ophthalmology found that elevated serum lipoprotein (a) [Lp(a)] ...

Finally, all statistical models included apo B to account for differences in the proatherogenic lipoprotein fraction. In the IDEAL study, we observed that plasma levels of HDL-C were indeed ...